APA (7th ed.) Citation

S, E., J, B., A, I., I, L., A, D. M., JS, L., . . . O, R. (2024). Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts. HIV medicine, 25(4), 440. https://doi.org/10.1111/hiv.13593

Chicago Style (17th ed.) Citation

S, Esser, et al. "Twelve-month Effectiveness and Safety of Bictegravir/emtricitabine/tenofovir Alafenamide in People with HIV: Real-world Insights from BICSTaR Cohorts." HIV Medicine 25, no. 4 (2024): 440. https://doi.org/10.1111/hiv.13593.

MLA (9th ed.) Citation

S, Esser, et al. "Twelve-month Effectiveness and Safety of Bictegravir/emtricitabine/tenofovir Alafenamide in People with HIV: Real-world Insights from BICSTaR Cohorts." HIV Medicine, vol. 25, no. 4, 2024, p. 440, https://doi.org/10.1111/hiv.13593.